AstraZeneca PLC (AZN.L)
| Previous close | 12,062.00 |
| Open | 12,194.00 |
| Bid | 12,206.00 x 0 |
| Ask | 12,210.00 x 0 |
| Day's range | 12,054.00 - 12,270.00 |
| 52-week range | 9,461.00 - 12,488.00 |
| Volume | |
| Avg. volume | 2,999,762 |
| Market cap | 189.22B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.91 |
| EPS (TTM) | 3.22 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 2.28 (1.89%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 125.61 |
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del., April 29, 2024--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
